<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390908</url>
  </required_header>
  <id_info>
    <org_study_id>R01AA022302</org_study_id>
    <secondary_id>R01AA022302</secondary_id>
    <nct_id>NCT02390908</nct_id>
  </id_info>
  <brief_title>Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings</brief_title>
  <acronym>PLUS</acronym>
  <official_title>Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter College of City University of New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunter College of City University of New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol use is increasingly recognized as a key factor in morbidity and mortality among&#xD;
      HIV-positive individuals and represents an important public health concern, given its&#xD;
      associations with medication non-adherence, increases in viral load, poor immunologic&#xD;
      outcomes (lower cluster of differentiation 4, or CD4, counts), drug resistance, lower health&#xD;
      care utilization, comorbidities (HIV/viral hepatitis coinfection), and poor health outcomes&#xD;
      overall. Adherence to HIV medications has a double public health benefit, both in terms of&#xD;
      slowing disease progression and improving health outcomes among HIV-positive individuals and&#xD;
      in helping to curb the sexual transmission of HIV. The objective of this study is to&#xD;
      implement a multisite comparative effectiveness trial in real-world clinical settings with&#xD;
      three intensities of treatment to test the clinical and cost effectiveness of an efficacious,&#xD;
      theory-based behavioral intervention (PLUS) in improving adherence to antiretroviral therapy&#xD;
      (ART) and alcohol-related outcomes among HIV-positive individuals who drink alcohol at&#xD;
      harmful or hazardous levels. The study is being conducted in collaboration between the Center&#xD;
      for HIV Educational Studies and Training (CHEST) at Hunter College at the City University of&#xD;
      New York (CUNY) and the Spencer Cox Center for Health at the Institute for Advanced Medicine,&#xD;
      Mount Sinai Health System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol consumption at harmful or hazardous levels among HIV-positive persons exacerbates&#xD;
      health problems and accelerates HIV disease progression. Antiretroviral therapy (ART) has&#xD;
      been the single most important treatment for people living with HIV to optimize viral&#xD;
      suppression and slow disease progression. Adherence to ART has considerable public health&#xD;
      implications, particularly given that optimal adherence decreases morbidity and mortality,&#xD;
      decreases the potential for the development of drug resistant strains of HIV, and reduces HIV&#xD;
      infectiousness.&#xD;
&#xD;
      Project PLUS (Positive Living through Understanding and Support) was the first (and to our&#xD;
      knowledge only) theory-based behavioral intervention, which integrates motivational&#xD;
      interviewing and cognitive-behavioral skills training, to demonstrate significant&#xD;
      improvements in viral load, CD4 cell count, and self-reported adherence among a racially and&#xD;
      ethnically diverse sample of HIV-positive women and men enrolled in a randomized controlled&#xD;
      trial, and the first intervention for hazardous drinkers to demonstrate any significant&#xD;
      effects. A clinic-based replication is the crucial next step in studying the intervention's&#xD;
      effectiveness in the real world when delivered by HIV clinic providers to their patients.&#xD;
&#xD;
      In collaboration with medical providers at the Spencer Cox Center for Health at the Institute&#xD;
      for Advanced Medicine, Mount Sinai Health System, the largest provider of HIV medical care in&#xD;
      the New York City area, our goals are to better understand alcohol-related outcomes among&#xD;
      HIV-positive persons over the lifespan and to conduct a multisite comparative effectiveness&#xD;
      trial with three intensities of treatment-the PLUS intervention, an enhanced treatment as&#xD;
      usual (eTAU) condition, and treatment as usual (TAU) condition-to test the clinical and&#xD;
      cost-effectiveness of the PLUS intervention in reducing alcohol use and improving ART&#xD;
      adherence, viral load, and CD4 counts among HIV-positive hazardous drinkers. This study has&#xD;
      the potential to exert a sustained and powerful impact on the effectiveness of ART&#xD;
      interventions for HIV-positive persons with problematic drinking.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2013</start_date>
  <completion_date type="Actual">May 8, 2018</completion_date>
  <primary_completion_date type="Actual">May 8, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>most recent result within past 90 days</time_frame>
    <description>Standard of care HIV-1 viral load results were run using local laboratories and results were abstracted from EMR data, indicating the participant's most recent viral load result. Each viral load result indicates the number of HIV copies in a milliliter (copies/mL), and raw values were log-transformed to deal with non-normal distribution. Minimum and maximum log-viral load values in the current sample were 1.28 and 6.07, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 Count</measure>
    <time_frame>most recent result within past 90 days</time_frame>
    <description>CD4 results were accessed through clinic EMR data, and represent cells per cubic millimeter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ART Medication Adherence</measure>
    <time_frame>past 30 days</time_frame>
    <description>Percentage of antiretroviral medication (ART) doses that were taken as prescribed, within the past 30 days. Minimum and maximum values were 0% and 100%, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol Use Severity</measure>
    <time_frame>past 90 days</time_frame>
    <description>Severity of alcohol consumption as measured by the Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 10-item, widely-used screening questionnaire consisting of three questions related to drinking frequency, three questions on dependence, and four questions on problems caused by alcohol over the past three months. Scores range from 0 to 40, with higher scores indicating greater alcohol use.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>HIV</condition>
  <condition>Alcohol Use</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>Site 1 Immediate PLUS intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-list PLUS condition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received the PLUS intervention at 12 months post baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Site 2 Immediate PLUS intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Site 3 Immediate PLUS intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Immediate PLUS intervention</intervention_name>
    <description>The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
    <arm_group_label>Site 1 Immediate PLUS intervention</arm_group_label>
    <arm_group_label>Site 2 Immediate PLUS intervention</arm_group_label>
    <arm_group_label>Site 3 Immediate PLUS intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Wait-list PLUS intervention</intervention_name>
    <description>In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
    <arm_group_label>Wait-list PLUS condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  Currently receiving ART&#xD;
&#xD;
          -  Current viral load (VL) Ëƒ200 copies/ml&#xD;
&#xD;
          -  Report drinking at hazardous levels, operationalized as exceeding 14 standard drinks&#xD;
             per week for men or exceeding 7 standard drinks per week for women, or reported use of&#xD;
             illicit drugs exclusive of marijuana or illicit use of prescription opioids within the&#xD;
             past 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyrel J Starks, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunter College of City University of New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for HIV/AIDS Educational Studies and Training of Hunter College, CUNY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):443-50.</citation>
    <PMID>18077833</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <results_first_submitted>November 13, 2020</results_first_submitted>
  <results_first_submitted_qc>April 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2021</results_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunter College of City University of New York</investigator_affiliation>
    <investigator_full_name>Tyrel Starks</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>alcohol use</keyword>
  <keyword>hazardous drinking</keyword>
  <keyword>behavioral intervention</keyword>
  <keyword>ART adherence</keyword>
  <keyword>viral load</keyword>
  <keyword>CD4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02390908/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>174 participants were enrolled in the experimental arms of PLUS. An additional 120 comparison patients, in regular care at sites but not enrolled in the study, had their electronic medical records (EMR) accessed. They were not considered enrolled in the study, as they did not sign informed consent, and did not receive intervention. Data for this &quot;No-Treatment EMR Control&quot; group included viral load, CD4 and demographics but not study measures (alcohol and drug use severity, medication adherence).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Site 1 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="P2">
          <title>Site 2 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="P3">
          <title>Site 3 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="P4">
          <title>Wait-list PLUS Condition</title>
          <description>Received the PLUS intervention at 12 months post-baseline&#xD;
PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.&#xD;
Wait-list PLUS intervention: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
        </group>
        <group group_id="P5">
          <title>No-Treatment EMR Control Group</title>
          <description>The EMRs of randomly selected patients who belonged to the TAU site and were not enrolled in the PLUS trial were matched on key patient characteristics for comparisons with EMRs of patients in the PLUS intervention and Waitlist control conditions. This matched cohort of patients received care at a fourth clinic that did not receive any intervention (i.e., PLUS or eTAU) and was considered as a natural history comparison group.&#xD;
This group were only included in analyses comparing VL and CD4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="90"/>
                <participants group_id="P5" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="90"/>
                <participants group_id="P5" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Site 1 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="B2">
          <title>Site 2 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="B3">
          <title>Site 3 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="B4">
          <title>Wait-list PLUS Condition</title>
          <description>Received the PLUS intervention at 12 months post baseline&#xD;
PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.&#xD;
Wait-list PLUS intervention: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
        </group>
        <group group_id="B5">
          <title>No-Treatment EMR Control Group</title>
          <description>Patients whose electronic medical records (EMRs) were extracted for viral load and CD4 outcomes over the study period, but who were not enrolled in PLUS and did not receive the intervention.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="90"/>
            <count group_id="B5" value="120"/>
            <count group_id="B6" value="294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="90"/>
                    <count group_id="B5" value="120"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="119"/>
                    <measurement group_id="B6" value="288"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="90"/>
                    <count group_id="B5" value="120"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="11.5"/>
                    <measurement group_id="B2" value="41.2" spread="11.3"/>
                    <measurement group_id="B3" value="44.0" spread="10.2"/>
                    <measurement group_id="B4" value="45.5" spread="11.9"/>
                    <measurement group_id="B5" value="45.2" spread="10.7"/>
                    <measurement group_id="B6" value="44.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="90"/>
                    <count group_id="B5" value="120"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="99"/>
                    <measurement group_id="B6" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="90"/>
                    <count group_id="B5" value="120"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="62"/>
                    <measurement group_id="B6" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="90"/>
                    <count group_id="B5" value="120"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="120"/>
                    <measurement group_id="B6" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drug Use DAST Score</title>
          <description>Drug Abuse Screening Test (DAST-10; Skinner, 1982). This measure was used to characterize a participant's drug use and consequences in the past three months. Participants respond yes (yes = 1) or no (no = 0) to nine items such as &quot;Are you always able to stop using drugs when you want to?&quot;. Total/summed scores on the DAST-10 range from 0 to 9, with higher scores indicating greater drug use and associated problems.</description>
          <population>Drug Use data is only available for the 174 participants who received the intervention. The 120 patients whose EMR records were extracted for viral load and CD4 results did not have data for this variable and were thus not included in analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="90"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="2.7"/>
                    <measurement group_id="B2" value="4.0" spread="2.5"/>
                    <measurement group_id="B3" value="2.8" spread="2.3"/>
                    <measurement group_id="B4" value="3.74" spread="2.7"/>
                    <measurement group_id="B6" value="3.74" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Standard of care HIV-1 viral load results were run using local laboratories and results were abstracted from EMR data, indicating the participant's most recent viral load result. Each viral load result indicates the number of HIV copies in a milliliter (copies/mL), and raw values were log-transformed to deal with non-normal distribution. Minimum and maximum log-viral load values in the current sample were 1.28 and 6.07, respectively.</description>
        <time_frame>most recent result within past 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Site 1 Immediate PLUS Intervention</title>
            <description>Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O2">
            <title>Site 2 Immediate PLUS Intervention</title>
            <description>Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O3">
            <title>Site 3 Immediate PLUS Intervention</title>
            <description>Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O4">
            <title>Wait-list PLUS Condition</title>
            <description>Received the PLUS intervention at 12 months post baseline&#xD;
Wait-list PLUS intervention: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
          </group>
          <group group_id="O5">
            <title>No-Treatment Control EMR Group</title>
            <description>120 matched patients in the No-Treatment Control Group whose Viral Load results were obtained through Electronic Medical Records (EMR)</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Standard of care HIV-1 viral load results were run using local laboratories and results were abstracted from EMR data, indicating the participant's most recent viral load result. Each viral load result indicates the number of HIV copies in a milliliter (copies/mL), and raw values were log-transformed to deal with non-normal distribution. Minimum and maximum log-viral load values in the current sample were 1.28 and 6.07, respectively.</description>
          <units>Log-transformed copies per. milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.7"/>
                    <measurement group_id="O2" value="1.8" spread="1.0"/>
                    <measurement group_id="O3" value="1.8" spread="0.6"/>
                    <measurement group_id="O4" value="2.6" spread="1.4"/>
                    <measurement group_id="O5" value="2.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 1 and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 1 on log-transformed Viral Load was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.94</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 2 and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 2 on log-transformed Viral Load was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 3's Immediate Delivery Group and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 3 on log-transformed Viral Load was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 3 (the Waitlist condition) and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>The main effect of being in the Waitlist condition (i.e., not receiving the PLUS intervention at Site 3) on log-transformed Viral Load was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 estimated here represents linear change in log VL across the 3-,6-,9- and 12-month follow-ups for Site 1 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 estimated here represents linear change in log VL across the 3-,6-,9- and 12-month follow-ups for Site 2 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 here represents linear change in log VL across the 3-,6-,9- and 12-month follow-ups for Site 3 (Immediate) relative to the No-Treatment EMR Control.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 estimated here represents linear change in log VL across the 3-,6-,9- and 12-month follow-ups for Waitlist relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.82</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in log VL across the 12-,15-, and 18-month follow-ups for Site 1 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in log VL across the 12-,15-, and 18-month follow-ups for Site 2 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in log VL across the 12-,15-, and 18-month follow-ups for Site 3 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in log VL across the 12-,15-, and 18-month follow-ups for Waitlist relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4 Count</title>
        <description>CD4 results were accessed through clinic EMR data, and represent cells per cubic millimeter.</description>
        <time_frame>most recent result within past 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Site 1 Immediate PLUS Intervention</title>
            <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O2">
            <title>Site 2 Immediate PLUS Intervention</title>
            <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O3">
            <title>Site 3 Immediate PLUS Intervention</title>
            <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O4">
            <title>Wait-list PLUS Condition</title>
            <description>Received the PLUS intervention at 12 months post-baseline&#xD;
PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.&#xD;
Wait-list PLUS intervention: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
          </group>
          <group group_id="O5">
            <title>No-Treatment EMR Control Group</title>
            <description>The EMRs of randomly selected patients who belonged to the TAU site and were not enrolled in the PLUS trial were matched on key patient characteristics for comparisons with EMRs of patients in the PLUS intervention and Waitlist control conditions. This matched cohort of patients received care at a fourth clinic that did not receive any intervention (i.e., PLUS or eTAU) and was considered as a natural history comparison group.&#xD;
This group were only included in analyses comparing VL and CD4.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count</title>
          <description>CD4 results were accessed through clinic EMR data, and represent cells per cubic millimeter.</description>
          <units>number of cells per cubic milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.4" spread="355.1"/>
                    <measurement group_id="O2" value="696.2" spread="356.2"/>
                    <measurement group_id="O3" value="390.5" spread="462.9"/>
                    <measurement group_id="O4" value="398.2" spread="252.2"/>
                    <measurement group_id="O5" value="409.1" spread="254.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 1 and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.68</ci_lower_limit>
            <ci_upper_limit>58.53</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 1 on CD4 Count was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 2 and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>23.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.54</ci_lower_limit>
            <ci_upper_limit>115.51</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 2 on CD4 Count was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 3's Immediate Delivery Group and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>-23.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-88.82</ci_lower_limit>
            <ci_upper_limit>41.40</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 3 on CD4 Count was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 3 (the Waitlist condition) and the No-Treatment Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>4.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.76</ci_lower_limit>
            <ci_upper_limit>58.14</ci_upper_limit>
            <estimate_desc>The main effect of being in the Waitlist condition (i.e., not receiving the PLUS intervention at Site 3) on log-transformed Viral Load was estimated against the No-Treatment Control EMR Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 estimated here represents linear change in CD4 count across the 3-,6-,9- and 12-month follow-ups for Site 1 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>7.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.88</ci_lower_limit>
            <ci_upper_limit>35.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 estimated here represents linear change in CD4 count across the 3-,6-,9- and 12-month follow-ups for Site 2 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-24.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-66.78</ci_lower_limit>
            <ci_upper_limit>16.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 estimated here represents linear change in CD4 count across the 3-,6-,9- and 12-month follow-ups for Site 3 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>18.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.63</ci_lower_limit>
            <ci_upper_limit>43.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 1 estimated here represents linear change in CD4 count across the 3-,6-,9- and 12-month follow-ups for Waitlist relative to No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>10.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.20</ci_lower_limit>
            <ci_upper_limit>30.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in CD4 count across the 12-,15-, and 18-month follow-ups for Site 1 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>6.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.24</ci_lower_limit>
            <ci_upper_limit>57.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in CD4 count across the 12-,15-, and 18-month follow-ups for Site 2 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-5.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.47</ci_lower_limit>
            <ci_upper_limit>74.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in log VL across the 12-,15-, and 18-month follow-ups for Site 3 relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.61</ci_lower_limit>
            <ci_upper_limit>62.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>Piecemeal latent growth curves (LGC) were specified with intercepts and linear slopes. Slope 2 estimated here represents linear change in log VL across the 12-,15-, and 18-month follow-ups for Waitlist relative to the No-Treatment EMR Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-38.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.51</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ART Medication Adherence</title>
        <description>Percentage of antiretroviral medication (ART) doses that were taken as prescribed, within the past 30 days. Minimum and maximum values were 0% and 100%, respectively.</description>
        <time_frame>past 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Site 1 Immediate PLUS Intervention</title>
            <description>Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O2">
            <title>Site 2 Immediate PLUS Intervention</title>
            <description>Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O3">
            <title>Site 3 Immediate PLUS Intervention</title>
            <description>Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O4">
            <title>Wait-list PLUS Condition</title>
            <description>Received the PLUS intervention at 12 months post baseline&#xD;
Wait-list PLUS intervention: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>ART Medication Adherence</title>
          <description>Percentage of antiretroviral medication (ART) doses that were taken as prescribed, within the past 30 days. Minimum and maximum values were 0% and 100%, respectively.</description>
          <units>percentage of adherent days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" spread="31.1"/>
                    <measurement group_id="O2" value="86.6" spread="15.8"/>
                    <measurement group_id="O3" value="83.4" spread="18.5"/>
                    <measurement group_id="O4" value="77.6" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 1 and the Waitlist Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>-7.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.52</ci_lower_limit>
            <ci_upper_limit>4.78</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 1 on ART Medication Adherence was estimated against Site 3's Waitlist Control Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 2 and the Waitlist Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and pre-baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>10.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.25</ci_lower_limit>
            <ci_upper_limit>26.82</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 2 on ART Medication Adherence was estimated against Site 3's Waitlist Control Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 3's Immediate Delivery Group and the Waitlist Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.63</ci_lower_limit>
            <ci_upper_limit>11.08</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention immediately at Site 3 on ART Medication Adherence was estimated against Site 3's Waitlist Control Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The slope estimated here represents linear change in Medication Adherence across the 3-, 6-, 9- and 12-month follow-ups for Site 1 relative to Waitlist Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>6.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>11.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The slope estimated here represents linear change in Medication Adherence across the 3-, 6-, 9- and 12-month follow-ups for Site 2 relative to Waitlist Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>3.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>11.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The slope estimated here represents linear change in Medication Adherence across 3-,6-,9- and 12-month follow-ups for Site 3 (Immediate) relative to Waitlist Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.85</ci_lower_limit>
            <ci_upper_limit>6.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Use Severity</title>
        <description>Severity of alcohol consumption as measured by the Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 10-item, widely-used screening questionnaire consisting of three questions related to drinking frequency, three questions on dependence, and four questions on problems caused by alcohol over the past three months. Scores range from 0 to 40, with higher scores indicating greater alcohol use.</description>
        <time_frame>past 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Site 1 Immediate PLUS Intervention</title>
            <description>Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O2">
            <title>Site 2 Immediate PLUS Intervention</title>
            <description>Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O3">
            <title>Site 3 Immediate PLUS Intervention</title>
            <description>Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
          </group>
          <group group_id="O4">
            <title>Wait-list PLUS Condition</title>
            <description>Received the PLUS intervention at 12 months post baseline&#xD;
Wait-list PLUS intervention: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Use Severity</title>
          <description>Severity of alcohol consumption as measured by the Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 10-item, widely-used screening questionnaire consisting of three questions related to drinking frequency, three questions on dependence, and four questions on problems caused by alcohol over the past three months. Scores range from 0 to 40, with higher scores indicating greater alcohol use.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.38" spread="6.6"/>
                    <measurement group_id="O2" value="3.29" spread="5.5"/>
                    <measurement group_id="O3" value="9.05" spread="9.6"/>
                    <measurement group_id="O4" value="5.93" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 1 and the Waitlist Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>3.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>5.78</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 1 on Alcohol Use severity (AUDIT) was estimated against Site 3's Waitlist Control Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 2 and the Waitlist Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.33</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention at Site 2 on Alcohol Use severity (AUDIT) was estimated against Site 3's Waitlist Control Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The intercept quoted here represents the difference between Site 3's Immediate Delivery Group and the Waitlist Group at the 3-month follow-up.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Beta</param_type>
            <param_value>4.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>7.54</ci_upper_limit>
            <estimate_desc>The main effect of receiving the PLUS intervention immediately at Site 3 on Alcohol Use severity (AUDIT) was estimated against Site 3's Waitlist Control Group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The slope estimated here represents linear change in AUDIT across the 3-, 6-, 9- and 12-month follow-ups for Site 1 relative to that for the Waitlist Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.47</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.50</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The slope estimated here represents linear change in AUDIT across the 3-, 6-, 9- and 12-month follow-ups for Site 2 relative to that for the Waitlist Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>A latent growth curve (LGC) with an intercept and linear slope was specified. The slope estimated here represents linear change in AUDIT across the 3-, 6-, 9- and 12-month follow-ups for Site 3 (Immediate) relative to Waitlist Control Group.</p_value_desc>
            <method>Latent Growth Curve</method>
            <method_desc>Analysis adjusted for gender and baseline value of the outcome.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Site 1 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="E2">
          <title>Site 2 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="E3">
          <title>Site 3 Immediate PLUS Intervention</title>
          <description>Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)&#xD;
Immediate PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.</description>
        </group>
        <group group_id="E4">
          <title>Wait-list PLUS Condition</title>
          <description>Received the PLUS intervention at 12 months post baseline&#xD;
PLUS intervention: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.&#xD;
Wait-list PLUS intervention: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.</description>
        </group>
        <group group_id="E5">
          <title>No-Treatment EMR Control Group</title>
          <description>Patients not enrolled in PLUS and did not receive the intervention, and were not monitored for adverse events (and thus, no data exists in this regard).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample was recruited in a major metropolitan area and may not be representative of the wider HIV-positive US population</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Tyrel J. Starks</name_or_title>
      <organization>Hunter College</organization>
      <phone>212-772-5550</phone>
      <email>tstarks@hunter.cuny.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

